Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial
dc.rights.license | open | en_US |
dc.contributor.author | COELHO, Lara E | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | CHAZALLON, Corine | |
dc.contributor.author | LAUREILLARD, Didier | |
dc.contributor.author | ESCADA, Rodrigo | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | N'TAKPE, Jean-Baptiste | |
dc.contributor.author | TIMANA, Isabelle | |
dc.contributor.author | MESSOU, Eugene | |
dc.contributor.author | EHOLIE, Serge | |
dc.contributor.author | KHOSA, Celso | |
dc.contributor.author | CHAU, Giang D | |
dc.contributor.author | CARDOSO, Sandra Wagner | |
dc.contributor.author | VELOSO, Valdilea G | |
dc.contributor.author | DELAUGERRE, Constance | |
dc.contributor.author | MOLINA, Jean-Michel | |
dc.contributor.author | GRINSZTEJN, Beatriz | |
hal.structure.identifier | Bordeaux population health [BPH] | |
hal.structure.identifier | Global Health in the Global South [GHiGS] | |
dc.contributor.author | MARCY, Olivier | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | DE CASTRO, Nathalie | |
dc.date.accessioned | 2024-04-30T15:19:32Z | |
dc.date.available | 2024-04-30T15:19:32Z | |
dc.date.issued | 2024-03-01 | |
dc.identifier.issn | 2328-8957 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/199553 | |
dc.description.abstractEn | BACKGROUND: After antiretroviral therapy (ART) initiation, people with HIV (PWH) treated for tuberculosis (TB) may develop TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Integrase inhibitors, by providing a faster HIV-RNA decline than efavirenz, might increase the risk for this complication. We sought to assess incidence and determinants of TB-IRIS in PWH with TB on raltegravir- or efavirenz-based ART. METHODS: We conducted a secondary analysis of the Reflate TB 2 trial, which randomized ART-naive PWH on standard TB treatment, to receive raltegravir- or efavirenz-based ART. The primary objective was to evaluate the incidence of TB-IRIS. Incidence rate ratio comparing TB-IRIS incidence in each arm was calculated. Kaplan-Meier curves were used to compare TB-IRIS-free survival probabilities by ART arm. Cox regression models were fitted to analyze baseline characteristics associated with TB-IRIS. RESULTS: Of 460 trial participants, 453 from Brazil, Côte d'Ivoire, Mozambique, and Vietnam were included in this analysis. Baseline characteristics were median age 35 years (interquartile range [IQR], 29-43), 40% female, 69% pulmonary TB only, median CD4, 102 (IQR, 38-239) cells/mm³, and median HIV RNA, 5.5 (IQR, 5.0-5.8) log copies/mL. Forty-eight participants developed TB-IRIS (incidence rate, 24.7/100 PY), 19 cases in the raltegravir arm and 29 in the efavirenz arm (incidence rate ratio 0.62, 95% confidence interval .35-1.10). Factors associated with TB-IRIS were: CD4 ≤ 100 cells/μL, HIV RNA ≥500 000 copies/mL, and extrapulmonary/disseminated TB. CONCLUSIONS: We did not demonstrate that raltegravir-based ART increased the incidence of TB-IRIS compared with efavirenz-based ART. Low CD4 counts, high HIV RNA, and extrapulmonary/disseminated TB at ART initiation were associated with TB-IRIS. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject.en | HIV/AIDS | |
dc.subject.en | IRIS | |
dc.subject.en | Antiretroviral therapy | |
dc.subject.en | Randomized controlled trial | |
dc.subject.en | Tuberculosis | |
dc.title.en | Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial | |
dc.title.alternative | Open Forum Infect Dis | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1093/ofid/ofae035 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 38486816 | en_US |
bordeaux.journal | Open Forum Infectious Diseases | en_US |
bordeaux.page | ofae035 | en_US |
bordeaux.volume | 11 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 3 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | GHIGS_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
bordeaux.identifier.funderID | Institut de Recherche pour le Développement | en_US |
hal.identifier | hal-04564640 | |
hal.version | 1 | |
hal.date.transferred | 2024-04-30T15:19:36Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.date=2024-03-01&rft.volume=11&rft.issue=3&rft.spage=ofae035&rft.epage=ofae035&rft.eissn=2328-8957&rft.issn=2328-8957&rft.au=COELHO,%20Lara%20E&CHAZALLON,%20Corine&LAUREILLARD,%20Didier&ESCADA,%20Rodrigo&N'TAKPE,%20Jean-Baptiste&rft.genre=article |